Vanderbilt University researchers have partnered with Mapp Biopharmaceutical Inc. to develop new human antibody therapies for people exposed to the deadly Ebola and Marburg viruses.
James Crowe Jr., MD, right, looks on as graduate student Andrew Flyak adjusts equipment in the Vanderbilt Vaccine Center used in the production of anti-Ebola antibodies.
Vanderbilt University researchers have partnered with Mapp Biopharmaceutical Inc. to develop new human antibody therapies for people exposed to the deadly Ebola and Marburg viruses.
The San Diego-based company has developed an experimental treatment, called ZMapp, which contains antibodies manufactured in plants. ZMapp has prevented lethal disease in rhesus monkeys but has not yet been tested for safety and efficacy in humans.
At Vanderbilt, researchers are using a high-efficiency method to isolate and generate large quantities of human antibodies from the blood of people who have survived Ebola and Marburg infections and who are now healthy. No live virus is used in the research here.
The goal of the collaboration is to develop safe and effective antibody therapies that can provide short-term protection to health care workers and others at risk of exposure to the two hemorrhagic filoviruses, which kill in part by causing massive bleeding.
“Our laboratory has been isolating antibodies to major human pathogens such as Ebola in order to understand the basic science of immunity in humans,” says lead Vanderbilt researcher James Crowe Jr., MD, the Ann Scott Carrell Professor and director of the Vanderbilt Vaccine Center. “However, with the current urgent medical need for treatments for Ebola infection, we are thrilled to be working with Mapp Biopharmaceutical to produce the antibodies we have discovered as antiviral drugs that may benefit patients and healthcare workers facing this terrible epidemic."
The current Ebola outbreak, which began in West Africa last December, has killed more than 2,500 people, making it the deadliest outbreak since the virus was discovered in 1976. Health officials say the true death toll may be three or four times greater.
“Dr. James Crowe’s success at isolating potent and effective human monoclonal antibodies against a wide range of infectious diseases is well recognized,” says company president Larry Zeitlin, PhD. “Mapp Biopharmaceutical is delighted to collaborate with him to develop human therapeutics against a range of public health threats.”
Monoclonal antibodies are made from a single clone of B cells, a type of white blood cell, that have been fused to myeloma cells to form fast-growing “hybridomas.” This allows researchers to quickly generate large quantities of antibodies against specific viral targets.
“We’re the only lab in the world that has a high-efficiency human hybridoma technique for isolating human monoclonal antibodies,” Crowe says.
The method, developed over the last 15 years, was instrumental in isolating antibodies from the blood of people who survived the worldwide 1918 influenza pandemic as well as antibodies to avian influenza, dengue and other current viral threats.
Crowe said his 12-person team is currently studying antibody responses to about 30 different viruses. “We’re also working with Vanderbilt collaborators on bacteria - staph and Clostridium difficile infection, a leading cause of hospital-associated diarrhea,” he says.
Vanderbilt’s research on Ebola and Marburg is being conducted in conjunction with the University of Texas Medical Branch in Galveston with support from the U.S. Department of Defense and the National Institutes of Health.
Source: Vanderbilt University Medical Center
Dear Helpdesk: Working in a Toxic Health Care Environment
March 28th 2024Dear Helpdesk is your steadfast companion, offering life coaching and workplace advice from 2 seasoned IPs for some of your most challenging real-life situations. Let us help you navigate the intersection between work and life, guiding you to navigate the dynamic world of infection prevention with confidence and grace. This article is on handling a toxic health care environment.
Product Locator: Spring and Early Mother's Day Gift Guide for Infection Prevention Personnel
March 27th 2024Whether it's a spring holiday, birthdays, or no reason at all, infection prevention personnel love to give and receive gifts that help at the end of a stressful day. Infection Control Today® offers some gift ideas for infection prevention personnel and their families.
Catching Up With Vangie Dennis, AORN 2022-2023 President at AORN 2024
March 26th 2024Infection Control Today (ICT) had the privilege of catching up with Vangie Dennis, MSN, RN, CNOR, CMLSO, at the Association of periOperative Registered Nurses' (AORN’s) International Surgical Conference & Expo 2024. As the former president of AORN and an esteemed figure in perioperative services, Vangie Dennis shared insights into her recent endeavors and the exciting new chapter she's embarked upon.
How To Optimize Your Time Management Strategies for the Busy Infection Preventionist
March 25th 2024Is your calendar resembling a chaotic masterpiece of overlapping tasks? Join the club of infection preventionists striving to balance responsibilities. Dive into proven strategies from a fellow infection preventionist to reclaim control of your time, streamline tasks, and boost productivity effectively. This is an IP Lifeline article.